Clinical Trials
22
Active:1
Completed:2
Trial Phases
5 Phases
Phase 1:2
Phase 2:5
Phase 3:6
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials
Phase 3
6 (31.6%)Not Applicable
5 (26.3%)Phase 2
5 (26.3%)Phase 1
2 (10.5%)Phase 4
1 (5.3%)PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma
Not Applicable
Recruiting
- Conditions
- Hodgkin LymphomaHodgkin DiseaseAdvanced Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2025-10-06
- Last Posted Date
- 2025-10-06
- Lead Sponsor
- National Research Center for Hematology, Russia
- Target Recruit Count
- 30
- Registration Number
- NCT07209059
- Locations
- 🇷🇺
National Medical Research Center for Hematology, Moscow, Russia
An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative Disorders
Not yet recruiting
- Conditions
- Non-Hodgkin Lymphoma, B-cellAcute Lymphoblastic Leukemia ALL
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- National Research Center for Hematology, Russia
- Target Recruit Count
- 60
- Registration Number
- NCT06721598
- Locations
- 🇷🇺
National Medical Research Center for Hematology, Moscow, Russian Federation
A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative Disorders
Phase 1
Recruiting
- Conditions
- Non-Hodgkin Lymphoma, B-cellAcute Lymphoblastic Leukemia ALL
- Interventions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- National Research Center for Hematology, Russia
- Target Recruit Count
- 60
- Registration Number
- NCT06705530
- Locations
- 🇷🇺
National Medical Research Center for Hematology, Moscow, Russian Federation
IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML
Phase 3
Recruiting
- Conditions
- Early Relapses of Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- National Research Center for Hematology, Russia
- Target Recruit Count
- 198
- Registration Number
- NCT06418776
- Locations
- 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation
MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients
Not Applicable
Recruiting
- Conditions
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Interventions
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- National Research Center for Hematology, Russia
- Target Recruit Count
- 200
- Registration Number
- NCT06237192
- Locations
- 🇷🇺
Olga Aleshina, Moscow, Russian Federation
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found